Discovery of PF-04449913, a Potent and Orally Bioavailable Inhibitor of Smoothened

[摘要]：Inhibitors of the Hedgehog signaling pathway have generated a great deal of interest in the oncology area due to the mounting evidence of their potential to provide promising therapeutic options for patients. Herein, we describe the discovery strategy to overcome the issues inherent in lead structure I that resulted in the identification of Smoothened inhibitor 14(2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyan ophenyl)urea (PF-04449913, 26), which has been advanced to human clinical studies.

[全文传递流程]：

一般上传文献全文的时限在1个工作日内